# Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

> **NCT03019640** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 22 (actual)

## Conditions studied

- Mantle Cell Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Follicular Lymphoma
- Recurrent Indolent Adult Non-Hodgkin Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Follicular Lymphoma
- Refractory Indolent Adult Non-Hodgkin Lymphoma

## Interventions

- **PROCEDURE:** Autologous Hematopoietic Stem Cell Transplantation
- **DRUG:** Carmustine
- **BIOLOGICAL:** Cord Blood-derived Expanded Allogeneic Natural Killer Cells
- **DRUG:** Cytarabine
- **DRUG:** Etoposide
- **BIOLOGICAL:** Filgrastim
- **DRUG:** Lenalidomide
- **DRUG:** Melphalan
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT03019640
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-10
- **Primary completion:** 2021-08-16
- **Final completion:** 2021-08-16
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2023-02-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03019640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03019640, "Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03019640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*